CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Organovo Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Organovo Holdings Inc
Suite 100, 11555 Sorrento Valley Road
Phone: (858) 224-1000p:858 224-1000 SAN DIEGO, CA  92121  United States Ticker: ONVOONVO
Business Summary
Organovo Holdings, Inc. is a clinical-stage biotechnology company. The Company is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Principal Executive Officer, Corporate Secretary Keith E.Murphy 51 8/25/2023 2/1/2012
President, Chief Financial Officer Tom P.Hess 59 10/6/2021 10/6/2021
Director - Discovery Biology, Director VaidehiJoshi 37 4/1/2022 3/8/2022
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Samsara Sciences, Inc. 6275 Nancy Ridge Drive San Diego CA United States

Business Names
Business Name
ONVO
Opal Merger Sub, Inc.
Organovo, Inc.
Real Estate Restoration & Rental, Inc.
SAMSARA SCIENCES

General Information
Number of Employees: 12 (As of 5/1/2024)
Outstanding Shares: 15,365,825 (As of 9/30/2024)
Shareholders: 82
Stock Exchange: NASD
Federal Tax Id: 271488943
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024